近日,《Oxidative Medicine and Cellular Longevity》发表了我院副院长李勇莉副教授为第一作者撰写的研究论文《p53-Mediated PI3K/AKT/mTOR Pathway Played a Role in PtoxDpt-Induced EMT Inhibition in Liver Cancer Cell Lines》(Volume 2019, Article ID 2531493, https://doi.org/10.1155/2019/2531493)。2018年《Oxidative Medicine and Cellular Longevity》位列中科院期刊分区2区,2017年影响因子4.936。这是李勇莉副教授继2018年发表的《Growth Inhibition of a Novel Iron Chelator, DpdtC, against Hepatoma Carcinoma Cell Lines Partly Attributed to Ferritinophagy-Mediated Lysosomal ROS Generation》之后又一高水平科研论文。
文章指出,多功能铁螯合剂PtoxDpt不仅抑制拓扑异构酶Ⅱ,也是p53诱导剂。同时PtoxDpt还能抑制上皮-间质转化(EMT)从而抑制肿瘤的侵袭转移,机制研究揭示PtoxDpt上述作用是通过p53/PI3K/AKT/mTOR信号途径发挥作用。
论文地址:https://www.hindawi.com/journals/omcl/2019/2531493/
(文、图/王斌)